Evaluation of Safety and Effectiveness of Stryker Surpass Evolve™ Flow Diverter System

Inclusion Criteria:

1. Age is ≥ 18 and ≤ 80 years

2. Has a single unruptured target intracranial aneurysm (IA) with the followingcharacteristics:

3. Is located on the internal carotid artery (ICA) or its branches.

4. Has a neck ≥ 4 mm, dome to neck ratio ≤ 2.0, or no discernible neck

5. Aneurysm size is ≤ 12 mm (saccular or fusiform configuration)

6. Has a parent vessel diameter ≥ 1.75 mm and ≤ 5.0 mm at both the proximal and distalsegments where the implant will be placed

7. Has multiple increased risk factors for intracranial (IA) aneurysm rupture,including but not limited to, aneurysm morphology, smoking, hypertension, diabetes,age, prior and/or family history of rupture, and/or history of subarachnoidhemorrhage that may result in a benefit risk profile of endovascular treatment thatoutweighs the risks of intracranial aneurysm rupture during the subject's expectedlifetime if left untreated.

Exclusion Criteria:

1. Has an extradural target aneurysm

2. Has a target aneurysm in the posterior circulation

3. Perforator or branch vessel, inclusive of the posterior communicating artery, arisesfrom the target aneurysm body or neck (branches or arteries must arise or connectfrom the parent vessel separate from the aneurysm or neck to not be excluded fromstudy)

4. Has a true bifurcation aneurysm, defined as an aneurysm (saccular or non-saccular)located at a point of vessel bifurcation

5. Target aneurysm is unsuitable for flow diverter treatment

6. Has vessel characteristics, such as severe tortuosity (cICA Type IV), stenosis (>70%), or morphology that would preclude safe endovascular access to the targetaneurysm necessary for treatment with the study device

7. Received previous treatment of the target aneurysm or parent artery where it wouldinterfere with the placement or proper apposition of the device

8. Has a medical contraindication to study or procedure related antiplateletmedications (aspirin, clopidogrel/Plavix, ticagrelor, and heparin), local or generalanesthesia, or life-threatening allergy to contrast dye

9. Has a known severe allergy to nickel, chromium cobalt, tungsten or platinum.

10. Modified Rankin Score (mRS) assessment is ≥ 3 at preprocedure exam

11. Presence of unstable neurological deficit (i.e., worsening of clinical condition inthe last 30 days)

12. Subarachnoid hemorrhage occurred within 30 days prior to enrollment

13. Major surgery (including previous intracranial implant) occurred within previous 30days or is planned in the next 120 days after enrollment date

14. Has more than one IA that requires treatment within 12 months

15. Received previous intracranial implant associated with the symptomatic or vasculardistribution within the past 12 weeks prior to treatment date

16. Chronic anticoagulation therapy is ongoing or known coagulopathy exists

17. Has other known serious concurrent medical conditions such as heart disease (e.g.,unstable atrial fibrillation [with or without pacemaker], recent myocardialinfarction [< 12 weeks ago], symptomatic congestive heart failure, or carotidstenosis), kidney failure [>2.0mg/dl serum creatinine], pulmonary disease,uncontrolled diabetes, progressive neurologic disorders, terminal cancer,vasculitis, high risk of ischemic stroke or recent stroke

18. Has acute life-threatening illness other than the neurological disease (e.g., acutekidney or heart failure) to be treated in this trial

19. Life expectancy is less than 5 years due to other illness or condition (in additionto an intracranial aneurysm)

20. Unable to complete study follow up due to dementia or psychiatric problem, substanceabuse, or history of noncompliance with medical advice

21. Pregnancy at time of enrollment

22. Presence of intracranial mass (tumor, except meningioma, abscess, or otherinfection), non-treated arteriovenous malformation (AVM) in the territory of thetarget aneurysm

23. Evidence of active infection at the time of treatment

24. Enrollment in another trial involving an investigational product that could confoundthe outcomes of this trial